Quick Answer
Cue Biopharma, Inc. reported Stockholders Equity of $26.43 million for fiscal year 2025.
Cue Biopharma, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $26.43M | +51.0% |
| 2024 | $17.50M | -52.8% |
| 2023 | $37.09M | -43.5% |
| 2022 | $65.68M | +0.3% |
| 2021 | $65.49M | -17.0% |
| 2020 | $78.91M | +44.6% |
| 2019 | $54.58M | +60.7% |
| 2018 | $33.97M | -44.9% |
| 2017 | $61.61M | +306.0% |
| 2016 | $15.17M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $13.25M | -47.8% | -27.1% |
| June 30, 2025 | $18.16M | -16.0% | +176.0% |
| March 31, 2025 | $6.58M | -78.1% | -62.4% |
| December 31, 2024 | $17.50M | -52.8% | -31.0% |
| September 30, 2024 | $25.37M | -40.5% | +17.3% |
| June 30, 2024 | $21.62M | -53.0% | -28.0% |
| March 31, 2024 | $30.04M | -45.4% | -19.0% |
| December 31, 2023 | $37.09M | -43.5% | -13.1% |
- Cue Biopharma, Inc. showed an increase of +51.0% in Stockholders Equity compared to the prior fiscal year.
- Over the 2016–2025 period, Cue Biopharma, Inc.’s stockholders equity has grown by 74.2% (from $15.17 million to $26.43 million).
- The most recent figure is from Cue Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: